Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
RecruitingOBSERVATIONAL
Enrollment
2,916
Participants
Timeline
Start Date
January 1, 2019
Primary Completion Date
December 31, 2031
Study Completion Date
December 31, 2031
Conditions
HER2-positive Breast Cancer
Trial Locations (1)
100044
RECRUITING
Peking University People's Hospital, Beijing
All Listed Sponsors
lead
Shu Wang
OTHER
NCT06722612 - Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer | Biotech Hunter | Biotech Hunter